›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:PredicineCARE™
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
PredicineType:
CE Marked
Related tests:
PredicineCARE™ is a pan-cancer 152-gene CLIA-certified cfDNA assay for treatment selection. It analyzes tumor-associated genetic aberrations to provide comprehensive molecular insights into a patient’s tumor biology to help determine whether targeted therapies are a treatment option. The assay analyzes genes directly linked to specific cancers by well documented scientific research
Cancer:
Bladder Cancer
Gene:
ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene), BRCA (Breast cancer early onset), EGFR (Epidermal growth factor receptor)
See More ...
ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene), BRCA (Breast cancer early onset), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), HER-2 (Human epidermal growth factor receptor 2), HRD (Homologous Recombination Deficiency), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), MYC (V-myc avian myelocytomatosis viral oncogene homolog), NTRK (Neurotrophic receptor tyrosine kinase), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), RET (Ret Proto-Oncogene), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
Confirmatory trial(s)
Confirmatory trial(s)